A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2011, filed Mar 28, 2012. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DXR SEC filings page.
Daxor Corporation (DXR) reported $1.4M in revenue for fiscal year 2011, down 8.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Daxor’s figures show a development-stage operation where research and overhead overwhelm a small revenue base despite positive gross margins.
Gross margin increased1.0 pp as revenue fell8.4% , separating product-level economics from the company’s broader cost structure. Operating margin deteriorated41.7 pp to-400.1% , showing that the main constraint was spending required to operate, not the direct cost of sales.
The 2011 net loss of
R&D consumed
Financial Health Signals
Daxor Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Daxor Corporation scores 1.32, below the 1.81 distress threshold. The score is pulled down most by an operating loss of $5.8M against total assets of $85.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Daxor Corporation passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Daxor Corporation reported a net loss of $7.2M while operations used $6.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Daxor Corporation earned -$0.35 per diluted share (EPS) in Q4 2011. This represents a decrease of 166.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q4 2011.
Not reported for Q4 2011.
Not reported for Q4 2011.
Cash & Balance Sheet
Daxor Corporation recorded an outflow of $995K in free cash flow in Q4 2011, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Daxor Corporation held $60K in cash as of Q4 2011; no long-term debt figure is on record for that period.
Daxor Corporation paid $0.10 per share in dividends in Q4 2011. This represents a decrease of 84.6% from the same quarter a year earlier.
Margins & Returns
None of these metrics is reported for Q4 2011.
Capital Allocation
Daxor Corporation spent $230K on share buybacks in Q4 2011, returning capital to shareholders by reducing shares outstanding. This represents an increase of 3617.8% from the same quarter a year earlier. Against the prior quarter it is up 214974.8%.
Daxor Corporation invested $5K in capex in Q4 2011, funding long-term assets and infrastructure. This represents a decrease of 86.6% from the same quarter a year earlier. Against the prior quarter it is down 91.9%.
Not reported for Q4 2011.
DXR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'1110-K | Q3'1110-Q | Q2'1110-Q | Q4'1010-K | Q3'1010-Q | Q2'1010-Q |
|---|---|---|---|---|---|---|
| Revenue | N/A | $341K-24.8% | $358K-2.8% | N/A | $453K | $368K |
| Cost of Revenue | N/A | $149K-19.6% | $161K-2.8% | N/A | $186K | $165K |
| Gross Profit | N/A | $192K-28.4% | $197K-2.7% | N/A | $268K | $203K |
| R&D Expenses | N/A | $637K-8.3% | $670K-8.8% | N/A | $695K | $735K |
| SG&A Expenses | N/A | $816K-4.9% | $871K-10.5% | N/A | $858K | $973K |
| Operating Income | N/A | -$1.3Mn/m | -$1.3Mn/m | N/A | -$1.3M | -$1.5M |
| EBITDA | N/A | -$1.2Mn/m | N/A | N/A | -$1.2M | N/A |
| Interest Expense | N/A | $30K+46.5% | $81K+811.1% | N/A | $20K | $9K |
| Income Tax | N/A | -$2.8M-258.1% | -$182Kn/m | N/A | $1.8M | -$40K |
| Net Income | N/A | -$4.2M-260.6% | -$185K-198.0% | N/A | $2.6M | $188K |
| EPS (Basic) | -$0.35-166.0% | -$0.99-259.7% | -$0.04-200.0% | $0.53 | $0.62 | $0.04 |
| EPS (Diluted) | -$0.35-166.0% | -$0.99-259.7% | -$0.04-200.0% | $0.53 | $0.62 | $0.04 |
Not reported in any period shown, so not listed: Diluted Shares (Avg).
DXR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'1110-K | Q3'1110-Q | Q2'1110-Q | Q4'1010-K | Q3'1010-Q | Q2'1010-Q |
|---|---|---|---|---|---|---|
| Total Assets | $85.7M-6.0% | $88.3M | $96.2M | $91.2M | N/A | N/A |
| Current Assets | $81.7M-6.1% | $84.1M | $92.1M | $87.0M | N/A | N/A |
| Cash & Equivalents | $60K+3.3% | $30K-72.2% | $112K-47.6% | $58K | $107K | $213K |
| Short-Term Investments | $55.8M+3.6% | $52.3Mn/m | $54.1Mn/m | $53.9M | $0 | $0 |
| Inventory | $302K-17.1% | $313K | $357K | $364K | N/A | N/A |
| Accounts Receivable | $220K+22.9% | $190K | $193K | $179K | N/A | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 |
| Total Liabilities | $49.5M+12.0% | $50.6M | $50.7M | $44.2M | N/A | N/A |
| Current Liabilities | $49.3M+12.2% | $50.4M | $50.4M | $43.9M | N/A | N/A |
| Non-Current Liabilities | $244K-18.7% | $259K | $273K | $300K | N/A | N/A |
| Total Equity | $36.2M-22.9% | $37.6M | $45.6M | $47.0M | N/A | N/A |
| Retained Earnings | $24.7M-25.0% | $26.7M | $30.8M | $33.0M | N/A | N/A |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
DXR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'1110-K | Q3'1110-Q | Q2'1110-Q | Q4'1010-K | Q3'1010-Q | Q2'1010-Q |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$990Kn/m | -$613Kn/m | N/A | -$1.8M | -$1.2M | N/A |
| Depreciation & Amortization | $71K-3.4% | $72K-2.0% | N/A | $74K | $74K | N/A |
| Capital Expenditures | $5K-86.6% | $58K-35.8% | N/A | $35K | $91K | N/A |
| Free Cash Flow | -$995Kn/m | -$671Kn/m | N/A | -$1.9M | -$1.3M | N/A |
| Investing Cash Flow | -$8.1M-224.8% | -$3.3Mn/m | N/A | $6.5M | -$109K | N/A |
| Financing Cash Flow | $9.1Mn/m | $3.8M+210.8% | N/A | -$4.7M | $1.2M | N/A |
| Dividends Paid | $421K-84.7% | $0-100.0% | N/A | $2.7M | $1.1M | N/A |
| Share Buybacks | $230K+3617.8% | $107-99.9% | N/A | $6K | $126K | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation.
DXR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'1110-K | Q3'1110-Q | Q2'1110-Q | Q4'1010-K | Q3'1010-Q | Q2'1010-Q |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | 56.2%-2.8pp | 55.1%0.0pp | N/A | 59.0% | 55.1% |
| Operating Margin | N/A | -369.9% | -375.2% | N/A | -283.5% | -408.6% |
| Net Margin | N/A | -1227.2% | -51.5%-102.7pp | N/A | 574.7% | 51.1% |
| Return on Equity | N/A | -11.1% | -0.4% | N/A | N/A | N/A |
| Return on Assets | N/A | -4.7% | -0.2% | N/A | N/A | N/A |
| Current Ratio | 1.66-0.3x | 1.67 | 1.83 | 1.98 | N/A | N/A |
| Liabilities-to-Equity | 1.37+0.4x | 1.35 | 1.11 | 0.94 | N/A | N/A |
| Asset Turnover | N/A | 0.00 | 0.00 | N/A | N/A | N/A |
| FCF Margin | N/A | -197.0% | N/A | N/A | -289.7% | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Daxor Corporation DXR | FY2011 | $1.4M | -$7.2M | N/A | $54.9M | — |
| JIN MEDICAL INTERNATIONAL LTD. ZJYL | FY2025 | $20.7M | $1.2M | 5.8% | $148.8M | 45/100 |
| Pro-Dex Inc New PDEX | FY2026 | $77.5M | $13.7M | 17.6% | $201.7M | 72/100 |
| Milestone Scientific, Inc. MLSS | FY2025 | $9.0M | -$5.7M | -63.8% | $28.1M | 40/100 |
Where Daxor Corporation Ranks
Frequently Asked Questions
What is Daxor Corporation's annual revenue?
Daxor Corporation (DXR) reported $1.4M in total revenue for fiscal year 2011. This represents a -8.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Daxor Corporation's revenue growing?
Daxor Corporation (DXR) revenue declined by 8.4% year-over-year, from $1.6M to $1.4M in fiscal year 2011.
Is Daxor Corporation profitable?
No, Daxor Corporation (DXR) reported a net loss of $7.2M in fiscal year 2011.
What is Daxor Corporation's EBITDA?
Daxor Corporation (DXR) had EBITDA of -$5.5M in fiscal year 2011, measuring earnings before interest, taxes, depreciation, and amortization.
What is Daxor Corporation's gross margin?
Daxor Corporation (DXR) had a gross margin of 54.9% in fiscal year 2011, indicating the percentage of revenue retained after direct costs of goods sold.
Does Daxor Corporation pay dividends?
Yes, Daxor Corporation (DXR) paid $0.25 per share in dividends during fiscal year 2011.
What is Daxor Corporation's return on equity (ROE)?
Daxor Corporation (DXR) has a return on equity of -19.8% for fiscal year 2011, measuring how efficiently the company generates profit from shareholder equity.
What is Daxor Corporation's free cash flow?
Daxor Corporation (DXR) recorded an outflow of $6.6M in free cash flow during fiscal year 2011. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Daxor Corporation's operating cash flow?
Daxor Corporation (DXR) recorded an outflow of $6.5M in operating cash flow during fiscal year 2011, representing cash used by core business activities.
What are Daxor Corporation's total assets?
Daxor Corporation (DXR) had $85.7M in total assets as of fiscal year 2011, including both current and long-term assets.
What are Daxor Corporation's capital expenditures?
Daxor Corporation (DXR) invested $123K in capital expenditures during fiscal year 2011, funding long-term assets and infrastructure.
How much does Daxor Corporation spend on research and development?
Daxor Corporation (DXR) invested $2.7M in research and development during fiscal year 2011.
What is Daxor Corporation's current ratio?
Daxor Corporation (DXR) had a current ratio of 1.66 as of fiscal year 2011, which is generally considered healthy.
What is Daxor Corporation's liabilities-to-equity ratio?
Daxor Corporation (DXR) had a liabilities-to-equity ratio of 1.37 as of fiscal year 2011, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2011, because the filing data we hold for that year carries no long-term debt figure.
What is Daxor Corporation's return on assets (ROA)?
Daxor Corporation (DXR) had a return on assets of -8.4% for fiscal year 2011, measuring how efficiently the company uses its assets to generate profit.
What is Daxor Corporation's P/E ratio?
Daxor Corporation (DXR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2011). The market capitalization is $54.9M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Daxor Corporation's price-to-sales ratio?
Daxor Corporation (DXR) trades at 37.9x sales, its market capitalization divided by $1.4M revenue, FY2011. The market capitalization is $54.9M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Daxor Corporation's liquidity compare with its operating cash outflow?
At the end of fiscal year 2011, Daxor Corporation (DXR) held $55.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.5M over that year. Dividing the one by the other, the reported balance equals about 103 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Daxor Corporation's Altman Z-Score?
Daxor Corporation (DXR) has an Altman Z-Score of 1.32, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Daxor Corporation's Piotroski F-Score?
Daxor Corporation (DXR) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Daxor Corporation's earnings high quality?
Daxor Corporation (DXR) reported a net loss of $7.2M while operations used $6.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.